Clinical Trials
Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced initial data from its Phase 2 study showing that a single 50 µg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals...
Clinical Trials
Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced at Vaxart’s key opinion leader event that new data obtained from its Phase I COVID-19 trial added to the...
Clinical Trials
Kintor Pharmaceuticals Announces Successful Proxalutamide COVID-19 Phase III Clinical Trial Initiation and Patient Dosing in U.S.
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the phase III clinical trial of proxalutamide for the treatment of male patients with mild or moderate COVID-19 symptoms in the United States...
Clinical Trials
Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization
Thermo Fisher Scientific Inc., the world leader in serving science, and PPD, Inc., a leading global provider of clinical research services to the pharma and biotech industry, announced that their boards of directors have approved a definitive agreement under...
Clinical Trials
Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day
Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced clinical and supply updates on its COVID-19 Vaccine program. New results from a preclinical study of the Company’s COVID-19 variant-specific vaccine candidates showed that the Company’s...
Clinical Trials
Catalent Biologics Completes Madison Facility Expansion to Double Clinical and Commercial Drug Substance Capacity
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it has completed the expansion of two new suites at its biologics drug...
Clinical Trials
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
Eli Lilly and Company and Incyte announced results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















